Ms. Svoronos has served as a member of GBT’s board of directors since December 2018. She has over 30 years of experience in the biopharmaceutical industry leading commercial functions. Dawn built a successful 25-year career at Merck & Co., where she led a variety of commercial groups in Canada, the US, Asia Pacific and Europe. At Merck, she most recently served as president for Europe/Canada, and previously served as president for Canada, vice-president for Asia Pacific and global brand leader for Merck’s Arthritis, Analgesics and Osteoporosis franchises. Ms. Svoronos currently serves on the board of directors of Theratechnologies, Xenon Pharmaceuticals, PTC Therapeutics and Adverum Biotechnologies. Ms. Svoronos received a B.A. in English and French literature from Carleton University in Ottawa, Ontario, Canada.